

**Population:** Women ages 67-85 who suffered a fracture\* **and** had either a bone mineral density test **or** received a osteoporosis prevention prescription.

**Measurement Range:** Bone mineral density test, 2 years prior fracture **or** received a prescription in the 6 months after fracture.

**Required Process/Codes:** Must include the bone mineral density test and results.

**Test CPT:** 76977-77078; 77080-77081; 77085-77086

**Results CPT II:** G8399; G8400

Qualifying prescriptions include bisphosphonates: alendronate-cholecalciferol, ibandronate, risedronate, zoledronic acid, calcitonin, teriparatide, denosumab, and raloxifene.

**Required Exclusion Codes:** \*Documented fracture of face, skull, finger or toe (S02.\*\*). BMD test during 24 months prior to the fracture, dispensed/active prescription to treat osteoporosis during 12 months prior to fracture, Claim/encounter for osteoporosis therapy during 12 months prior to fracture. G2081; G2090; G2091; G9690

**Outreach Logic:** Included in birthday cards and pre-appointment outreach for female patients ages 67-85 without a BMD/DXA in prior 2 years.